# GRI catalysts: GRI Bio, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/gri/catalysts

> GRI Bio, Inc. (GRI) has no upcoming catalysts in this calendar. The latest recorded is the Arazlo® (tazarotene) earnings report, May 14, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | GRI Bio, Inc. |
| Ticker | GRI (Nasdaq) |
| SEC CIK | 1824293 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/gri |

## Cash runway

Cash $9.5M as of 2026-09-30; quarterly burn $1.5M; about 19.3 months of runway at that rate (XBRL company facts, accession 0001824293-26-000070).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2023 | [Arazlo® (tazarotene) trial start](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed | "In December 2023, we commenced enrollment in our Phase 2a trial in IPF patients and we expect topline results from this trial to be available in the third quarter of 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000050/ck0001824293-20241231.htm)) |
| November 14, 2024 | [Arazlo® (tazarotene) earnings report](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed | "GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/ex991_pressreleaseq32024ea.htm)) |
| Q1 2025 | [Arazlo® (tazarotene) interim data readout](https://sec-api.dev/pdufa/tazarotene) | GRI |  | scheduled | "Based on our current enrollment projections, we now expect interim data from this trial to be available in the first quarter of 2025 and topline results to be available in the second quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1824293/000182429324000151/ck0001824293-20240930.htm)) |
| March 17, 2025 | [Arazlo® (tazarotene) earnings report](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed | "GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF")" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/ex991_pressreleaseye24earn.htm)) |
| Q2 2025 | [Arazlo® (tazarotene) topline data readout](https://sec-api.dev/pdufa/tazarotene) | GRI |  | scheduled | "Topline data of GRI-0621 readout expected in Q2 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429324000153/ex991_pressreleaseq32024ea.htm)) |
| Q2 2025 | [Arazlo® (tazarotene) interim data readout](https://sec-api.dev/pdufa/tazarotene) | GRI |  | scheduled | "Based on our current enrollment projections, we expect interim data from this trial to be available in the second quarter of 2025 and topline results to be available in the third quarter of 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000073/ck0001824293-20250331.htm)) |
| May 15, 2025 | [Arazlo® (tazarotene) earnings report](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed | "GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000072/ex991_pressreleaseq125earn.htm)) |
| Q3 2025 | [Arazlo® (tazarotene) interim data readout](https://sec-api.dev/pdufa/tazarotene) | GRI |  | scheduled | "We continue to make strides towards our anticipated interim data readout and topline data readout which remains on track for the second and third quarter of 2025, respectively." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000053/ex991_pressreleaseye24earn.htm)) |
| Q3 2025 | [Arazlo® (tazarotene) topline data readout](https://sec-api.dev/pdufa/tazarotene) | GRI |  | scheduled | "6-week interim biomarker data (n=24) expected in July 2025 and topline data expected in Q3 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000082/ex991_pressrelease6weeksaf.htm)) |
| Nov 2025 | [Arazlo® (tazarotene) topline data readout](https://sec-api.dev/pdufa/tazarotene) | GRI |  | scheduled | "We expect to release topline results from the Phase 2a biomarker study by the end of November 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000151/ck0001824293-20250930.htm)) |
| December 10, 2025 | [Arazlo® (tazarotene) topline data readout](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed, positive | "LA JOLLA, CA, December 10, 2025 -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced positive topline data from the Phase 2a GRI-0621-IPF-02 clinical trial evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429325000167/ex991_pressreleasetoplined.htm)) |
| February 4, 2026 | [GRI Bio, Inc. earnings report](https://sec-api.dev/companies/gri/catalysts) | GRI |  | completed | "LA JOLLA, CA, February 4, 2026 -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases today summarized recently reported Full Year 2025 financial results, provided an update on the Company's current cash position and cash runway and summarized key clinical and corporate highlights." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000040/ex991_pressreleaseye25earn.htm)) |
| May 14, 2026 | [Arazlo® (tazarotene) earnings report](https://sec-api.dev/pdufa/tazarotene) | GRI |  | completed | "GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000046/ex991_pressreleaseq126earn.htm)) |

## Drugs

- [Arazlo® (tazarotene)](https://sec-api.dev/pdufa/tazarotene): inflammatory, fibrotic and autoimmune diseases, today

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/gri/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "GRI catalysts: GRI Bio, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/gri/catalysts

```bibtex
@misc{secapidev_companies_gri_catalysts_20261116,
  title        = {GRI catalysts: GRI Bio, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/gri/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_gri_catalysts_20261116","title":"GRI catalysts: GRI Bio, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/gri/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
